LADA

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos